TNX-102 SL   Major Depressive Disorder
Phase 2 study planned 2H’26

TNX-102 SL   Acute Stress Disorder/Acute Stress Reaction
Investigator-Initiated Study
Phase 2 topline data planned 2H’26

TNX-1300   Cocaine Intoxication
Mid-Phase 2

TNX-4800   Prevention of Lyme Disease in the U.S.
Adaptive Phase 2 field study planned 1H’27 pending FDA agreement

TNX-801   Prevention of Smallpox and Mpox
Preclinical

TNX-4200   Protect Against Viral Diseases
Preclinical
Anti-CD40 ligand mAb

TNX-1500   Prevention of Organ Transplant Rejection
Investigator-Initiated study
Phase 2 study planned 2H’26

TNX-1700   Gastric and Colorectal Cancer
Preclinical

TNX-4700   Immuno-oncology Indications
Preclinical

TNX-2900   Prader-Willi Syndrome
FDA Orphan Drug and Rare Pediatric Disease Designation
Phase 2 study planned 1Q’27